Welcome to our dedicated page for CODEXIS SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
CDXS filed a Form 144 reporting a proposed sale of 5,280 shares of Common Stock tied to an RSU vesting and settlement on 02/24/2026 through Morgan Stanley Smith Barney Executive Financial Services. The filing also lists recent insider dispositions by Stefan Lutz: 4,685 shares sold on 01/07/2026 for $7,949.51 and 2,492 shares sold on 02/06/2026 for $3,257.29.
Codexis, Inc. Chief Scientific Officer Stefan Lutz reported a small share sale tied to tax withholding. On February 6, 2026, he sold 2,492 shares of common stock at $1.3071 per share, solely to cover tax or other government withholding obligations from vesting restricted stock units.
After this transaction, Lutz beneficially owned 136,283 shares of Codexis common stock, which includes 35,799 restricted stock units. The filing shows he holds the shares directly.
Codexis, Inc. insider Georgia Erbez, the company’s Chief Financial Officer and Chief Business Officer, reported a sale of common stock tied to equity compensation. On February 6, 2026, Erbez sold 3,826 shares of Codexis common stock at $1.3071 per share, solely to cover tax or other government withholding obligations arising from the vesting of restricted stock units.
Following this transaction, Erbez beneficially owned 66,810 shares of Codexis common stock, which includes 24,374 restricted stock units. The filing indicates the holdings are owned directly rather than through an intermediary entity.
Codexis, Inc. President and CEO Alison Moore, who also serves as a director, reported selling 3,826 shares of Codexis common stock on February 6, 2026 at a price of $1.3071 per share. The filing explains that these shares were sold solely to cover tax or other government withholding obligations related to the vesting of restricted stock units.
After this transaction, Moore beneficially owned 250,506 shares of Codexis common stock, which includes 136,249 restricted stock units. The ownership is reported as held directly in her name.
An affiliate of the issuer filed a notice of proposed sale of 3,291 shares of common stock, with an aggregate market value of $4,179.57. The shares are expected to be sold on 02/06/2026 on the NASDAQ through Morgan Stanley Smith Barney Executive Financial Services.
These shares were acquired on 02/06/2026 via RSU vesting and settlement from the issuer as consideration for services rendered. In the preceding three months, Kevin Norrett sold 6,123 shares for $10,389.80 on 01/07/2026 and 1,745 shares for $2,914.32 on 01/16/2026.
Codexis associated holder filed a notice of proposed sale of 2,460 shares of Codexis common stock. The shares are expected to be sold through Morgan Stanley Smith Barney on or about February 6, 2026 on the NASDAQ.
The filing lists an aggregate market value of 3124.20 for the shares to be sold and notes that 90,324,383 shares of common stock were outstanding. The 2,460 shares were acquired on February 6, 2026 via RSU vesting and settlement as consideration for services rendered.
Opaleye Management Inc., Opaleye, L.P. and James Silverman report a significant passive stake in Codexis, Inc. common stock. They beneficially own 6,789,738 shares, representing 7.52% of Codexis’s common stock, with shared voting and shared dispositive power over these shares and no sole voting or dispositive power.
The ownership percentage is based on 90,324,383 Codexis common shares outstanding as of 11/03/2025, as reported in the company’s 10-Q. The adviser also manages separate accounts that collectively hold 120,000 Codexis shares, with each account owning less than 5% of the class. The reporting persons certify the holdings were not acquired and are not held for the purpose of changing or influencing control of Codexis.
Codexis executive Kevin Norrett filed a Rule 144 notice to sell 1,745 shares of Codexis common stock through Morgan Stanley Smith Barney LLC on or about 01/16/2026. The filing reports an aggregate market value of 2914.32 for these shares, with 90324383 common shares outstanding. The shares to be sold were acquired as restricted stock from the issuer on 01/01/2026, with 1,745 securities acquired on that date. The notice also discloses that during the past three months, Norrett sold 6115 and 8 common shares on 01/07/2026 for gross proceeds of 10376.08 and 13.72, respectively. By signing, the seller represents that he is not aware of any undisclosed material adverse information about Codexis.
Aberdeen Group plc and abrdn Inc. filed an amended Schedule 13G reporting their beneficial ownership of 7,966,498 shares of Codexis, Inc. common stock, representing 8.82% of the class as of 12/31/2025. All of these shares are reported with shared voting and shared dispositive power, with no sole voting or dispositive authority.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Codexis. abrdn Inc. holds the position on behalf of underlying clients, with Aberdeen Group plc as the parent company and abrdn Holdings Limited as an intermediate holding company.
Codexis, Inc. CSO Stefan Lutz reported selling 4,685 shares of Codexis common stock on January 7, 2026 at a price of $1.6968 per share. According to the disclosure, this sale was made to cover tax liabilities arising from the vesting and release of restricted stock units held by him. After this transaction, Lutz beneficially owned 138,775 shares of Codexis common stock, which includes 41,633 restricted stock units, all held directly.